


APAC Biotech gets patent for immunotherapy product

24 July 2020 | News

APAC has announced it will conduct clinical trials for highly aggressive brain tumors (GBM) and pancreatic cancers (PDAC) with its new technology



Delhi based APAC Biotech, a biotechnology company involved in extensive research on personalized immunotherapy using dendritic cells for over a decade, was finally granted Indian patent, entitled "Composition and method for producing activated dendritic cells."

The company has previously conducted trials and received the approval by the Drug Controller General of India in 2017 for its product APCEDEN. Being completely autologous in nature, it has been successfully infused to patients with an excellent safety profile and efficacy.

APAC Biotech's present invention provides a composition comprising of a population of activated dendritic cells tutored in the lab to produce immunogens useful in the treatment of cancer. The invention also provides a method for producing a population of activated dendritic cells specific to a patient's whole tumor protein. Most significantly, the procedures used to manufacture dendritic cells replicate the natural environment of the human host very closely.

APAC Biotech's new product is named LTR-MEMVAXRALEUCEL, which is a unique, advanced and never-been-used-before technology based on homogenous loading of the whole tumor amplified mRNA and whole tumor protein, specifically designed for Glioblastoma and Pancreatic Ductal Adenocarcinoma for which clinical trial is awaited, and APAC Biotech is in talks with various eminent hospitals and principal investigators to initiate the trial in India very soon.